Improved sensitivity for the quantification of oligonucleotides in plasma using microflow LC and accurate mass spectrometry

Cathy Lane PhD, Pharma & Peptide Quant Applications Lead EMEAI, SCIEX



Presentation outline

IMPROVED SENSITIVITY FOR THE QUANTIFICATION OF OLIGONUCLEOTIDES IN PLASMA USING MICROFLOW LC AND ACCURATE MASS SPECTROMETRY

- Background
- QTOF duty cycle & Zeno trapping on the ZenoTOF 7600 system
- Microflow LC
- Quantification of oligonucleotides in rat plasma
- Non-targeted impurity analysis
- Conclusions



BACKGROUND AND INTRODUCTION

- Typically, short strings of synthetic nucleotides
- Alter, suppress, or restore expression of target genes associated with disease or health
- Increasing numbers of companies are currently investigating oligonucleotide therapeutics to treat diseases
 - High specificity
 - Ability to reach formerly undruggable targets
- Two major therapeutic approaches:
 - Antisense oligonucleotides (ASOs)
 - short interfering RNA (siRNA)

Summary of some of the clinically approved oligonucleotides

Brand name [generic name]	Type of treatment	Target	Disease	Year of approval
Vitravene [formivirsen]	ASO	mRNA encoding IE2	CMV retinitis	1998
Macugen [pegaptanib]	Aptamer	VEGF165	AMD of the retina	2004
Kynamro [mipomersen]	ASO	ApoB-100 mRNA	Homozygous familial hypercholesterole mia	2013
Exondys 51 [eteplirsen]	SSO	DMD 001-gene (exon 51 target site)	Duchenne muscular dystrophy	2016
Spinraza [nusinersen]	ASO	SMN2 mRNA	Type 1, 2, and 3 spinal muscular atrophy	2016
Inotersen [tegsedi]	ASO	Transthyretin	Hereditary transthyretin amyloidosis	2018
Givosiran [Givlaari]	siRNA	Aminolevulinate synthase 1	Acute hepatic porphyria	2019



TYPES OF OLIGONUCLEOTIDE DRUGS

Targeted mRNA splice switching



Targeted mRNA degradation

Ribosome





The Power of Precision

OLIGONUCLEOTIDE MODIFICATIONS



Quantification of oligonucleotide therapeutics

DIFFERENT OPTIONS FOR OLIGONUCLEOTIDE QUANTIFICATION

- Hybridization Assay (ELISA): good sensitivity but limited selectivity & linear dynamic range
- LC-MS MRM : better selectivity & LDR, but lower sensitivity
- LC-HRMS : Good for characterization, but limited sensitivity for quantification because of low duty cycle





What is duty cycle?

... AND WHY IS DUTY CYCLE IMPORTANT?

- What is duty cycle?
 - % of ions injected into the TOF

an range upper

- Typically, ~5-25%
 - Dependent on
 - Fragment mass
- Why is duty cycle not 100%?
 - Ion losses occur when combining:
 - Pulsed measurement technique
 - TOF
 - Continuous ion beam
 - Quadrupole



Operation of the Zeno trap

FOR SENSITIVITY GAINS IN MS/MS

- The Zeno trap on the ZenoTOF 7600 system addresses the duty cycle problems with QTOFs by providing control of the ion beam from the collision cell into the accelerator
- lons are gated then released from the Zeno trap in an ordered fashion based on potential energy
 - Generally, higher m/z ions are released first, followed by lower m/z ions
 - A wide range of ions now arrive in the accelerator to be pushed during the same pulse



J. Am. Soc. Mass Spectrom. (2017) 28: 2143-2150)



➤ This results in improved MS/MS sensitivity across the entire mass range, with ≥ 90% of all ions injected into TOF region

Microflow LC

Sampling efficiency = fraction of ionized molecules in the liquid flow entering the MS More confined spray with higher concentration of analytes – easier to pull ions into the MS More efficient ionization - less solvent makes it easier to charge the analyte molecules



USING TRAP AND ELUTE TO LOAD LARGE VOLUMES WITH HIGH THROUGHPUT



Step 1 in trap and elute workflow

SAMPLE IS INJECTED INTO THE SAMPLE LOOP



The Power of Precision

Step 2 in trap and elute workflow

SAMPLE IS LOADED ONTO THE TRAP COLUMN



The Power of Precision

Step 3 in trap and elute workflow

SAMPLE IS ELUTED FROM THE TRAP COLUMN ONTO THE ANALYTICAL COLUMN AND ANALYZED



© 2021 DH Tech, Dev. Pte. Ltd.

The Power of Precision

14

Step 4 in trap and elute workflow

TRAP IS WASHED USING THE LOADING PUMP



15

The Power of Precision

A case study: quantification of oligonucleotides in rat plasma

- Objective: determine the quantification sensitivity for 4 antisense oligonucleotides
 - 3 Phosphorothioated 18- to-33-mer drug structures (fomivirsen, nusinersen and eluforsen)
 - 1 Phosphorothioated and 2'-O-methylated 20-mer ("methyl oligo")
- Rat plasma was prepared using 3 mL Clarity OTX cartridges (Phenomenex), following the Phenomenex protocol for oligonucleotides
- · Calibration curves were spiked into the prepared plasma
- A 23-mer standard DNA oligonucleotide was used as an internal standard (IS)
- Samples were analysed using trap & elute microflow LC on the ZenoTOF 7600 system, using MRM^{HR} with Zeno transing
- 16 trapping







LC method conditions

MICROFLOW LC WORKFLOW

LC system:	M5 MicroLC	Analytical pump 5 µL/min
Mobile phase A:	15 mM N,N-diisopropylethylamine, 35 mM hexafluoroisopropanol in water	1 000 Parip 0 parip 00 00 00 00 00 00 00 00 00 00 00 00 00
Mobile phase B:	15 mM N,N-diisopropylethylamine, 35 mM hexafluoroisopropanol in 90/10 methanol/water	0 5 Time (min.) VALVE POSITION LOAD INJECT L
Analytical gradient:	5-60% B in 3 min at 5 μL/min	100 Logding pump: 35 ul /mir
Loading:	0% B for 2 min at 35 µL/min	
Injection volume:	30 µL	20 8 8 8 8 9 8 9 9 9 9 9 9 9 9 9 9 9 9 9
Trap:	0.3 x 5 mm YMC-Triart 3 μm C18 @ 80ºC	0 0 5
Analytical column:	0.3 x 50 mm YMC-Triart 3 μm C18 @ 80ºC	



10

10

LOAD

MS method conditions

- Mass spectrometer: ZenoTOF 7600 system
- Source: OptiFlow Turbo V ion source with a low micro electrode
- Negative ionization
- MRM^{HR} mode
- Charge state that provided the most intense fragments selected for each analyte
- CE and DP optimized for best S/N on the selected fragment
- Accumulation time 0.03 sec (cycle time 0.4 sec)
- Q1 resolution LOW (for best S/N)

ID	Q1 mass (m/z)	Fragment (m/z)	DP (V)	CE (V)
Fomivirsen	741.4	319.02	-125	-33
Methyl-oligo	694.2	374.03	-135	-39
Nusinersen	790.9	393.05	-135	-40
Eluforsen	715.8	358.04	-135	-39
IS	786.3	303.04	-135	-49

Parameter	MS	MS/MS		
Scan mode	TOF MS	MRM ^{HR}		
Polarity	ne	gative		
Gas 1	2	20 psi		
Gas 2	4	10 psi		
Curtain gas	32 psi			
Source temperature	1	00°C		
lon spray voltage	-3	000 V		
Declustering potential	-	80 V		
CAD gas		12		
Start mass	500 m/z	100 m/z		
Stop mass	2,000 m/z	2,000 m/z		
Q1 resolution	NA	Low		
Accumulation time	0.1 s	0.03 s		
Collision energy	-10 V	See Table 4		
CE spread	0 V	0 V		
Zeno trap	NA	ON		
ZOD threshold (CID)	NA	20,000 cps		
Time bins to sum	6	12		
QJet ion guide RF amplitude	190 V	190 V		

Chromatography

TRAP-AND-ELUTE MICROFLOW METHOD



- TOF MS XIC for 4 target oligonucleotides plus internal standard (IS)
- All oligonucleotides are baseline separated
 - Baseline separation is important because overlap amongst precursors can occur due to the large number of charge states of each oligonucleotide



Blank and LLOQ for all analytes



Comparison of high flow and microflow



LLOQs and linear range

QUANTITATIVE PERFORMANCE

• LLOQ criteria:

LLOQ:

- CV < 20% and accuracy between 80% and 120%
- Any point above the LLOQ:

CV < 15% and accuracy between 85% and 115%

Analyte	LLOQ (ng/mL)	ULOQ (ng/mL)	Linearity (orders)	CV at LLOQ (%)	Accuracy at LLOQ (%)	 Calibration for Fomivirsen 2: y = 0.03441 x + 9.91300e-4 (r = 0.99583, r² = 0.99167) (weighting: 1 / x²) Calibration for Methyl-oligo 2: y = 0.01198 x + 1.18867e-4 (r = 0.99586, r² = 0.99173) (weighting: 1 / x²) Calibration for Nusinersen 2: y = 0.04906 x + 9.78047e-5 (r = 0.99599, r² = 0.99200) (weighting: 1 / x²) Calibration for Eluforsen 1: y = 0.00677 x + 1.17921e-4 (r = 0.99212, r² = 0.98429) (weighting: 1 / x²)
20-mer phosphorothioated and 2'-O-methylated antisense oligonucleotide (ASO)	0.03	300	4	16.2	98.3	LDR >3.5 orders of magnitude
Fomivirsen	0.03	300	4	11.2	96.3	¥ 4-
Nusinersen	0.01	100	4	3.7	96.0	2
Eluforsen	0.03	100	3.5	18.7	95.7	

The Power of Precision

Non-targeted impurity analysis

IDENTIFICATION AND RELATIVE QUANTIFICATION

- Reconstructed TOF-MS spectrum of nusinersen chromatographic peak
- Based on the accurate mass and isotope pattern, the SCIEX Molecule Profiler software identified the additional species as desulfurization and di-desulfurization products
 - Common impurities with one or two sulfur atoms exchanged with an oxygen
 - Likely from synthesis or storage. No evidence of in-source fragmentation (desulfurization products were chromatographically separated from the main product)





Non-targeted impurity analysis

IDENTIFICATION AND RELATIVE QUANTIFICATION

- Whilst no MRM^{HR} data was acquired for the desulfurization products, the relative amount versus the main product could be determined using the TOF-MS data
- The peak areas vs concentration were linear for both nusinersen and the desulfurization product
 - Using the most intense isotope of the TOF MS spectrum
 - On average, ratio of calculated area was 41% with a CV of 3.2%





- Low pg/mL LLOQs were achieved for ASOs in rat plasma using MRM^{HR} mode, the Zeno trap and microflow LC
- The TOF-MS data acquired as part of the MRM^{HR} workflow can be used for the identification and relative quantification of additional impurities/metabolites
- Analysis time using trap-and-elute microflow LC method was comparable to that of using an analytical flow LC method, resulting in similar sample throughput
- Reduced consumption of LC-MS grade ion-pairing reagents for microflow LC provides significant cost savings and increases LC-MS system robustness



- Xin Zhang
- Eshani Nandita
- Remco van Soest





The Power of Precision

Thank you for your attention





The Power of Precision

Questions and answers



The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-11-13593-B

